Insight Molecular Diagnostics Inc
NASDAQ:IMDX

Watchlist Manager
Insight Molecular Diagnostics Inc Logo
Insight Molecular Diagnostics Inc
NASDAQ:IMDX
Watchlist
Price: 5.215 USD 0.29% Market Closed
Market Cap: 149.5m USD

Net Margin
Insight Molecular Diagnostics Inc

-1 380.7%
Current
-3 161%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 380.7%
=
Net Income
-60.8m
/
Revenue
4.4m

Net Margin Across Competitors

No Stocks Found

Insight Molecular Diagnostics Inc
Glance View

Market Cap
149.3m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

IMDX Intrinsic Value
4.085 USD
Overvaluation 22%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 380.7%
=
Net Income
-60.8m
/
Revenue
4.4m
What is the Net Margin of Insight Molecular Diagnostics Inc?

Based on Insight Molecular Diagnostics Inc's most recent financial statements, the company has Net Margin of -1 380.7%.

Back to Top